104 related articles for article (PubMed ID: 17134824)
21. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.
Mesa C; Mirza M; Mitsutake N; Sartor M; Medvedovic M; Tomlinson C; Knauf JA; Weber GF; Fagin JA
Cancer Res; 2006 Jul; 66(13):6521-9. PubMed ID: 16818623
[TBL] [Abstract][Full Text] [Related]
22. Establishment and characterization of seven human breast cancer cell lines including two triple-negative cell lines.
Ku JL; Park SC; Kim KH; Jeon YK; Kim SH; Shin YK; Noh DY; Im SA; Bang YJ; Han W; Kim WH; Park JG
Int J Oncol; 2013 Dec; 43(6):2073-81. PubMed ID: 24141649
[TBL] [Abstract][Full Text] [Related]
23. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
24. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
Kondo T; Nakazawa T; Murata S; Kurebayashi J; Ezzat S; Asa SL; Katoh R
Hum Pathol; 2007 Dec; 38(12):1810-8. PubMed ID: 17714762
[TBL] [Abstract][Full Text] [Related]
25. Down-regulation of retinoic acid receptor beta in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells.
Swisshelm K; Ryan K; Lee X; Tsou HC; Peacocke M; Sager R
Cell Growth Differ; 1994 Feb; 5(2):133-41. PubMed ID: 8180126
[TBL] [Abstract][Full Text] [Related]
26. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells.
Schmutzler C; Winzer R; Meissner-Weigl J; Köhrle J
Biochem Biophys Res Commun; 1997 Nov; 240(3):832-8. PubMed ID: 9398654
[TBL] [Abstract][Full Text] [Related]
27. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
[TBL] [Abstract][Full Text] [Related]
28. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis.
Gauchotte G; Philippe C; Lacomme S; Léotard B; Wissler MP; Allou L; Toussaint B; Klein M; Vignaud JM; Bressenot A
Pathology; 2011 Aug; 43(5):447-52. PubMed ID: 21716161
[TBL] [Abstract][Full Text] [Related]
29. [BRAF gene mutation in thyroid cancer].
Kopczyńska E; Junik R; Tyrakowski T
Pol Merkur Lekarski; 2006 Feb; 20(116):210-3. PubMed ID: 16708643
[TBL] [Abstract][Full Text] [Related]
30. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis.
Giordano TJ; Kuick R; Thomas DG; Misek DE; Vinco M; Sanders D; Zhu Z; Ciampi R; Roh M; Shedden K; Gauger P; Doherty G; Thompson NW; Hanash S; Koenig RJ; Nikiforov YE
Oncogene; 2005 Oct; 24(44):6646-56. PubMed ID: 16007166
[TBL] [Abstract][Full Text] [Related]
31. Derivation and characterization of retinoid-resistant human embryonal carcinoma cells.
Moasser MM; Khoo KS; Maerz WJ; Zelenetz A; Dmitrovsky E
Differentiation; 1996 Jul; 60(4):251-7. PubMed ID: 8765055
[TBL] [Abstract][Full Text] [Related]
32. Expression of all-trans-retinoic acid receptor RNA in human thyroid cells.
del Senno L; Rossi R; Franceschetti P; degli Uberti EC
Biochem Mol Biol Int; 1994 Aug; 33(6):1107-15. PubMed ID: 7804136
[TBL] [Abstract][Full Text] [Related]
33. Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features.
Durand S; Ferraro-Peyret C; Joufre M; Chave A; Borson-Chazot F; Selmi-Ruby S; Rousset B
Endocr Relat Cancer; 2009 Jun; 16(2):467-81. PubMed ID: 19208736
[TBL] [Abstract][Full Text] [Related]
34. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
[TBL] [Abstract][Full Text] [Related]
35. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
Kumar A; Soprano DR; Parekh HK
Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
[TBL] [Abstract][Full Text] [Related]
36. [Genetic causes of the thyroid carcinomas].
Jindrichová S; Vlcek P; Bendlová B
Cas Lek Cesk; 2004; 143(10):664-8. PubMed ID: 15584614
[TBL] [Abstract][Full Text] [Related]
37. Abnormal expression of retinoic acid receptors and keratin 19 by human oral and epidermal squamous cell carcinoma cell lines.
Hu L; Crowe DL; Rheinwald JG; Chambon P; Gudas LJ
Cancer Res; 1991 Aug; 51(15):3972-81. PubMed ID: 1713123
[TBL] [Abstract][Full Text] [Related]
38. High frequency of retinoic acid receptor beta abnormalities in human lung cancer.
Gebert JF; Moghal N; Frangioni JV; Sugarbaker DJ; Neel BG
Oncogene; 1991 Oct; 6(10):1859-68. PubMed ID: 1717924
[TBL] [Abstract][Full Text] [Related]
39. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules.
Kim SK; Kim DL; Han HS; Kim WS; Kim SJ; Moon WJ; Oh SY; Hwang TS
Diagn Mol Pathol; 2008 Jun; 17(2):118-25. PubMed ID: 18382358
[TBL] [Abstract][Full Text] [Related]
40. Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation.
Malehmir M; Haghpanah V; Larijani B; Ahmadian S; Alimoghaddam K; Heshmat R; Ghavamzadeh A; Adabi K; Ghaffari SH
Mol Cell Endocrinol; 2012 Jan; 348(1):260-9. PubMed ID: 21924320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
